Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

September 4, 2019

PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France.

"We continue to be pleased with the promising efficacy and safety data of KSI-301," said Victor Perlroth, M.D., Kodiak's Chief Executive Officer. "At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301. The data being presented continue to demonstrate the potential for KSI-301 to be a first-line intravitreal anti-VEGF therapy."

Details of the presentations are below.

EURETINA 2019 Congress

Oral Presentation: Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: first-time results from a phase 1b study in patients with wAMD, DME and RVO
Presenter: Pravin U. Dugel, M.D. -- Clinical Professor, Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California; Managing Partner, Retinal Consultants of Arizona, Retinal Research Institute, Phoenix, AZ
Presentation date and time: Thursday, September 5, 2019 –11:59am CEST

Oral Presentation: Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO
Presenter: Pravin U. Dugel, M.D. -- Clinical Professor, Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California; Managing Partner, Retinal Consultants of Arizona, Retinal Research Institute, Phoenix, AZ
Presentation date and time: Sunday, September 8, 2019 – 9:48am CEST

The slide presentations will be available on the Kodiak Investor Relations website at http://ir.kodiak.com/ at the time of the presentations.

About KSI-301

KSI-301 is an investigational therapy built on the Company's ABC Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents. Kodiak's objective with KSI-301 is to improve real-world outcomes for patients with retinal vascular diseases and to enable earlier treatment and prevention of vision loss for patients with diabetic eye disease.

About Kodiak Sciences Inc.

Kodiak™ is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component. Kodiak is based in Palo Alto, CA. For more information, visit www.kodiak.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, future development plans, clinical and regulatory objectives and the timing thereof, anticipated design of planned clinical trials, expectations regarding the potential efficacy and commercial potential of our product candidates, including KSI-301, the anticipated presentation of data, the results of our research and development efforts and our ability to advance our product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, clinical trials may not demonstrate safety and efficacy of any of our product candidates; our efforts to advance the clinical development of additional product candidates may not be successful; any of our product candidates may fail in development; the preliminary safety, efficacy and durability data for our KSI-301 product candidate from the Phase 1 study will not continue or persist; cessation or delay of any of the ongoing clinical studies and/or our development of KSI-301 may occur; future potential regulatory milestones of KSI-301, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentations-at-euretina-meeting-300912050.html

SOURCE Kodiak Sciences Inc.

John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, ir@kodiak.com